Merck & Co., Inc.
Merck & Co., Inc. and Portola Enter Worldwide License Agreement to Develop and Commercialize Betrixaban, a Novel Investigational Oral Anticoagulant for Cardiovascular Disease
Published in Surgery Litigation and Law Weekly, July 24th, 2009
"Betrixaban represents an important addition to our late-stage portfolio with the potential to be a significant medicine in the Factor Xa inhibitor class," said Luciano Rossetti M.D., senior vice president and franchise head, Atherosclerosis and Cardiovascular, Merck Research Laboratories. "This agreement...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Surgery Litigation and Law Weekly
More Articles from Surgery Litigation and Law Weekly
- Breast Cancer Screening
New breast cancer screening study results reported from University of Washington, Medical Department - Dicerna Pharmaceuticals, Inc.
Dicerna Pharmaceuticals Announces Appointment of Industry Veteran David Madden as Chairman of the Board - Medicare and Medicaid
National Survey: Americans Fear Paying for Cancer Treatment As Much As Dying of the Disease - Abbott
Abbott and Oasmia Pharmaceutical Announce Exclusive Distribution Agreement for Paccal Vet, a New Chemotherapeutic Agent for Dogs - Abdominal Aortic Aneurysm
New abdominal aortic aneurysm research from Federal University discussed - Abdominal Aortic Aneurysm
Research conducted at Carnegie Mellon University has provided new information about abdominal aortic aneurysm - More from this issue of Surgery Litigation and Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
